Rezolute, Inc. (NASDAQ:RZLT) Director Wladimir Hogenhuis Purchases 6,758 Shares of Stock

Rezolute, Inc. (NASDAQ:RZLT) Director Wladimir Hogenhuis bought 6,758 shares of the business’s stock in a transaction that occurred on Monday, March 31st. The stock was acquired at an average cost of $2.92 per share, for a total transaction of $19,733.36. Following the completion of the purchase, the director now directly owns 84,025 shares of the company’s stock, valued at $245,353. The trade was a 8.75 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Wladimir Hogenhuis also recently made the following trade(s):

• On Tuesday, February 18th, Wladimir Hogenhuis acquired 10,000 shares of Rezolute stock. The shares were bought at an average cost of $4.70 per share, for a total transaction of $47,000.00.

Rezolute Price Performance

RZLT stock opened at $2.92 on Wednesday. Rezolute, Inc. has a 1-year low of $2.22 and a 1-year high of $6.19. The business has a 50 day simple moving average of $4.18 and a two-hundred day simple moving average of $4.72. The company has a market capitalization of $176.76 million, a price-to-earnings ratio of -2.39 and a beta of 0.95.

Rezolute (NASDAQ:RZLT) last released its quarterly earnings results on Wednesday, February 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.11. Sell-side analysts anticipate that Rezolute, Inc. will post -0.93 EPS for the current fiscal year.

Wall Street Analyst Weigh In

RZLT has been the topic of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and set a $14.00 target price on shares of Rezolute in a report on Thursday, February 13th. JMP Securities increased their price objective on Rezolute from $8.00 to $9.00 and gave the stock a “market outperform” rating in a report on Thursday, February 13th. Guggenheim restated a “buy” rating on shares of Rezolute in a report on Monday, February 10th. Finally, Craig Hallum upgraded shares of Rezolute to a “strong-buy” rating in a research note on Tuesday, February 4th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $24.38.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Point72 Asia Singapore Pte. Ltd. increased its stake in Rezolute by 48.5% during the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 19,799 shares of the company’s stock worth $97,000 after acquiring an additional 6,470 shares during the last quarter. JPMorgan Chase & Co. purchased a new position in shares of Rezolute in the 3rd quarter worth approximately $42,000. Charles Schwab Investment Management Inc. increased its position in shares of Rezolute by 65.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company’s stock valued at $112,000 after purchasing an additional 9,000 shares during the last quarter. Virtu Financial LLC raised its holdings in Rezolute by 58.0% during the 3rd quarter. Virtu Financial LLC now owns 26,026 shares of the company’s stock valued at $126,000 after buying an additional 9,551 shares during the period. Finally, Alpine Global Management LLC bought a new stake in Rezolute in the fourth quarter worth $54,000. Institutional investors own 82.97% of the company’s stock.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.